Sydorak Inna, Dang Ming, Baxter Sarah J, Halcomb Michael, Ma Peter, Kapila Sunil, Hatch Nan
Department of Orthodontics and Pediatric Dentistry, University of Michigan, Ann Arbor, USA.
Macromolecular Science and Engineering Center, University of Michigan, Ann Arbor, USA.
Eur J Orthod. 2019 Jan 23;41(1):1-8. doi: 10.1093/ejo/cjy017.
Because orthodontic tooth movement is dependent upon osteoclast-mediated resorption of alveolar bone adjacent to the pressure side of tooth roots, biologic mediators that regulate osteoclasts can be utilized to control tooth movement.
To develop a novel method to locally enhance orthodontic anchorage.
We encapsulated osteoprotegerin (OPG) in polymer microspheres and tested the effectiveness of microsphere encapsulated versus non-encapsulated OPG for enhancing orthodontic anchorage in a rodent model of tooth movement. A single injection of 1 mg/kg non-encapsulated or microsphere encapsulated OPG was delivered into the palatal mucosa mesial to the first maxillary molar 1 day prior to tooth movement. A positive control group received injections of 5 mg/kg non-encapsulated OPG every 3 days during tooth movement. After 28 days of tooth movement, hemi-maxillae and femurs were dissected. Molar mesial and incisor distal tooth movement was measured using stone casts that were scanned and magnified. Local alveolar, distant femur bone, and tooth root volumes were analyzed by micro computed tomography. Serum OPG levels were measured by ELISA. Osteoclast numbers were quantified by histomorphometry.
The single injection of microsphere encapsulated OPG significantly enhanced orthodontic anchorage, while the single injection of non-encapsulated OPG did not. Injection of encapsulated OPG inhibited molar mesial movement but did not inhibit incisor tooth movement, and did not alter alveolar or femur bone volume fraction, density, or mineral content. Multiple injections of 5 mg/kg non-encapsulated OPG enhanced orthodontic anchorage, but also inhibited incisor retraction and altered alveolar and femur bone quality parameters. Increased OPG levels were found only in animals receiving multiple injections of non-encapsulated 5 mg/kg OPG. Osteoclast numbers were higher upon tooth movement in animals that did not receive OPG. Osteoclast numbers in OPG injected animals were variable within groups.
Microsphere encapsulation of OPG allows for controlled drug release, and enhances site-specific orthodontic anchorage without systemic side effects. With additional refinements, this drug delivery system could be applicable to a broad array of potential biologic orthodontic therapeutics.
由于正畸牙齿移动依赖于破骨细胞介导的牙根压力侧相邻牙槽骨的吸收,因此可利用调节破骨细胞的生物介质来控制牙齿移动。
开发一种局部增强正畸支抗的新方法。
我们将骨保护素(OPG)包裹在聚合物微球中,并在啮齿动物牙齿移动模型中测试微球包裹的OPG与未包裹的OPG增强正畸支抗的效果。在牙齿移动前1天,将1mg/kg未包裹或微球包裹的OPG单次注射到上颌第一磨牙近中的腭黏膜中。阳性对照组在牙齿移动期间每3天接受5mg/kg未包裹的OPG注射。牙齿移动28天后,解剖半侧上颌骨和股骨。使用扫描并放大的石膏模型测量磨牙近中移动和切牙远中移动。通过微型计算机断层扫描分析局部牙槽骨、远处股骨和牙根体积。通过酶联免疫吸附测定法测量血清OPG水平。通过组织形态计量学对破骨细胞数量进行定量。
单次注射微球包裹的OPG可显著增强正畸支抗,而单次注射未包裹的OPG则不能。注射包裹的OPG可抑制磨牙近中移动,但不抑制切牙移动,且不改变牙槽骨或股骨的体积分数、密度或矿物质含量。多次注射5mg/kg未包裹的OPG可增强正畸支抗,但也抑制切牙后移并改变牙槽骨和股骨的质量参数。仅在接受多次注射5mg/kg未包裹OPG的动物中发现OPG水平升高。未接受OPG的动物在牙齿移动时破骨细胞数量更高。注射OPG的动物组内破骨细胞数量存在差异。
OPG的微球包裹可实现药物的可控释放,并增强局部特异性正畸支抗,且无全身副作用。经过进一步改进,这种药物递送系统可应用于广泛的潜在生物正畸治疗方法。